Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer Stock Is Plunging Today

By George Budwell - Mar 9, 2020 at 10:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's stock can't escape Monday's blood bath in the markets.

What happened

Big pharma titan Pfizer Inc. (PFE 0.78%) is having a painful morning. The drugmaker's shares dipped by as much as 5.4% in early morning trading Monday morning in response to the ongoing coronavirus outbreak. The main headline is that the virus has rapidly spread across Italy, Iran, South Korea, and the United States in recent days.

As a result, a worldwide recession, sparked by an interruption in global trading, appears to be a near certainty at this point. Pfizer's shares have rebounded slightly from their early morning swoon, but they are still down by 3.57% as of 9:58 a.m. EDT. 

A businessman with a laptop folded over his head holding a sign that reads "help!".

Image source: Getty Images.

So what

Pfizer has consistently been one of the worst performing stocks on the Dow Jones Industrial Average. Investors aren't thrilled with the drugmaker's plans to spin off its legacy products business and subsequently focus on branded medications. The overarching reason is that Pfizer will be losing a sizable chunk of its annual revenues by doing so, which may have a negative impact on its deal-making capacity and shareholder rewards program. The point is that Pfizer's shares were already in a tailspin before today's hefty downturn. Underscoring this point, the pharma giant's shares have now shed almost 15% of their value over the past 12 months. 

Now what

Should bargain hunters take advantage of this latest dip in Pfizer's stock? If you are a long-term investor -- meaning you are willing to hold a stock for 10 years or longer, the answer is a resounding yes. This big pharma stock sports a stellar dividend, a great pipeline, and it has a well-defined plan in place to create value for loyal shareholders. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.88 (0.78%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.